NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
Phase 1
Completed
- Conditions
- Adult Grade III Lymphomatoid GranulomatosisAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueIntraocular LymphomaNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-cell Leukemia/Lymphoma
- Interventions
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00098891
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
Phase 1
Completed
- Conditions
- Acute Undifferentiated LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Interventions
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2013-01-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00098826
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00098969
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇬🇧Leicester Royal Infirmary, Leicester, England, United Kingdom
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
Phase 2
Completed
- Conditions
- Smoldering Multiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceMultiple Myeloma
- Interventions
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2016-12-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 23
- Registration Number
- NCT00099047
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Recurrent Small Cell Lung CancerExtensive Stage Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT00098956
- Locations
- 🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
Phase 2
Terminated
- Conditions
- B-cell Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaProlymphocytic Leukemia
- Interventions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 64
- Registration Number
- NCT00098371
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma
Phase 3
Active, not recruiting
- Conditions
- DS Stage I Multiple MyelomaDS Stage II Multiple MyelomaDS Stage III Multiple Myeloma
- Interventions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 452
- Registration Number
- NCT00098475
- Locations
- 🇺🇸
Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States
🇺🇸The Medical Center of Aurora, Aurora, Colorado, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Phase 2
Completed
- Conditions
- Recurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityMetastatic Squamous Neck Cancer With Occult PrimaryRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavitySalivary Gland Squamous Cell CarcinomaStage IV Squamous Cell Carcinoma of the Hypopharynx
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2014-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 88
- Registration Number
- NCT00098631
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
Phase 1
Completed
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Interventions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00098423
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
Phase 2
Terminated
- Conditions
- Adenocarcinoma of the EsophagusAdenocarcinoma of the StomachRecurrent Esophageal CancerRecurrent Gastric Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00098527
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States